Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

Tandstad, T ; Ståhl, Olof LU ; Håkansson, Ulf LU ; Dahl, O ; Haugnes, H S ; Klepp, O H ; Langberg, C W ; Laurell, A ; Oldenburg, J and Solberg, A , et al. (2014) In Annals of Oncology 25(11). p.2167-2172
Abstract
SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Oncology
volume
25
issue
11
pages
2167 - 2172
publisher
Oxford University Press
external identifiers
  • pmid:25114021
  • wos:000344644200009
  • scopus:84918827743
  • pmid:25114021
ISSN
1569-8041
DOI
10.1093/annonc/mdu375
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)
id
f69f4c56-faa0-4731-bfae-d084e78b6a5d (old id 4614926)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25114021?dopt=Abstract
date added to LUP
2016-04-01 10:19:06
date last changed
2022-05-13 07:37:27
@article{f69f4c56-faa0-4731-bfae-d084e78b6a5d,
  abstract     = {{SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.}},
  author       = {{Tandstad, T and Ståhl, Olof and Håkansson, Ulf and Dahl, O and Haugnes, H S and Klepp, O H and Langberg, C W and Laurell, A and Oldenburg, J and Solberg, A and Söderström, K and Cavallin-Ståhl, Eva and Stierner, U and Wahlquist, R and Wall, N and Cohn-Cedermark, G}},
  issn         = {{1569-8041}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{2167--2172}},
  publisher    = {{Oxford University Press}},
  series       = {{Annals of Oncology}},
  title        = {{One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.}},
  url          = {{http://dx.doi.org/10.1093/annonc/mdu375}},
  doi          = {{10.1093/annonc/mdu375}},
  volume       = {{25}},
  year         = {{2014}},
}